Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 3
2016 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Minimal residual disease in multiple myeloma: bringing the bench to the bedside.
Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M, Landgren O. Mailankody S, et al. Nat Rev Clin Oncol. 2015 May;12(5):286-95. doi: 10.1038/nrclinonc.2014.239. Epub 2015 Jan 27. Nat Rev Clin Oncol. 2015. PMID: 25622976 Free PMC article. Review.
Many patients are now achieving a complete response to treatment, and consequently highly sensitive assays are needed for detection of minimal residual disease (MRD) in patients with MM. Results of multicolour flow cytometry and deep-sequencing …
Many patients are now achieving a complete response to treatment, and consequently highly sensitive assays are needed for detection of mi
Participation in the College of American Pathologists Laboratory Accreditation Program Decreases Variability in B-Lymphoblastic Leukemia and Plasma Cell Myeloma Flow Cytometric Minimal Residual Disease Testing: A Follow-up Survey.
Hupp MM, Bashleben C, Cardinali JL, Dorfman DM, Karlon W, Keeney M, Leith C, Long T, Murphy CE, Pillai V, Rosado FN, Seegmiller AC, Linden MA. Hupp MM, et al. Arch Pathol Lab Med. 2021 Mar 1;145(3):336-342. doi: 10.5858/arpa.2019-0493-CP. Arch Pathol Lab Med. 2021. PMID: 32886757 Free article.
CONTEXT.-: Minimal residual disease (MRD) testing by flow cytometry is ubiquitous in hematolymphoid neoplasm monitoring, especially B-lymphoblastic leukemia (B-ALL), for which it provides predictive information and guides managemen …
CONTEXT.-: Minimal residual disease (MRD) testing by flow cytometry is ubiquitous in hematolymphoi …
Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.
Keeney M, Halley JG, Rhoads DD, Ansari MQ, Kussick SJ, Karlon WJ, Mehta KU, Dorfman DM, Linden MA. Keeney M, et al. Arch Pathol Lab Med. 2015 Oct;139(10):1276-80. doi: 10.5858/arpa.2014-0543-CP. Epub 2015 Feb 19. Arch Pathol Lab Med. 2015. PMID: 25695342 Free article.
CONTEXT: Flow cytometry is often applied to minimal residual disease (MRD) testing in hematolymphoid neoplasia. Because flow-based MRD tests are developed in the laboratory, testing methodologies and lower levels of d …
CONTEXT: Flow cytometry is often applied to minimal residual disease (MRD) testing in hematolympho …
Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, de Tute R, Vergilio JA, Rawstron AC, Paiva B. Arroz M, et al. Cytometry B Clin Cytom. 2016 Jan;90(1):31-9. doi: 10.1002/cyto.b.21228. Epub 2015 Jun 2. Cytometry B Clin Cytom. 2016. PMID: 25619868 Free article.
BACKGROUND: Major heterogeneity between laboratories in flow cytometry (FC) minimal residual disease (MRD) testing in multiple myeloma (MM) must be overcome. Cytometry societies such as the International …
BACKGROUND: Major heterogeneity between laboratories in flow cytometry (FC) minimal residual di